bisFabs: Tools for rapidly screening hybridoma IgGs for their activities as bispecific antibodies

mAbs

Volumn 9, Issue 3, 2017, Pages 430-437

  Patke, Sanket ^a,b   Li, Ji ^a   Wang, Peiyin ^a   Slaga, Dion ^a   Johnston, Jennifer ^a   Bhakta, Sunil ^a   Panowski, Siler ^a,c   Sun, Liping L ^a   Junttila, Teemu ^a   Scheer, Justin M ^a,d   Ellerman, Diego A ^a  

^a GENENTECH INC   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c Pfizer Rinat   (United States)

^d Boerhinger Ingelheim   (Germany)

Author keywords

Antibody formats; bispecific antibody; bispecific screening; crosslinked Fabs

Indexed keywords

BISPECIFIC ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN F(AB) FRAGMENT;

ANIMAL EXPERIMENT; BIOPHYSICS; CELL KILLING; CONJUGATION; CYTOTOXICITY; GENE EXPRESSION; GENETIC SCREENING; HUMAN; HUMAN CELL; HYBRIDOMA; ION EXCHANGE CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PROTEIN DEGRADATION; PROTEIN PURIFICATION; SIZE EXCLUSION CHROMATOGRAPHY; ANIMAL; BIOSYNTHESIS; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROCEDURES; PROTEIN ENGINEERING;

ANIMALS; ANTIBODIES, BISPECIFIC; HUMANS; HYBRIDOMAS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; MICE; PROTEIN ENGINEERING;

EID: 85015652861     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2017.1281504     Document Type: Article

References (27)

1. Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today 2015; 20:838-47; PMID:25728220; http://dx.doi.org/10.1016/j.drudis.2015.02.008
2. Kontermann R, ed. Bispecific Antibodies:Springer, 2011; http://dx.doi.org/10.1007/978-3-642-20910-9
3. Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 2015; 67:95-106; PMID:25637431; http://dx.doi.org/10.1016/j.molimm.2015.01.003
4. Jones RG, Landon J. Enhanced pepsin digestion:a novel process for purifying antibody F(ab')(2) fragments in high yield from serum. J Immunol Methods 2002; 263:57-74; PMID:12009204; http://dx.doi.org/10.1016/S0022-1759(02)00031-5
5. Mariani M, Camagna M, Tarditi L, Seccamani E. A new enzymatic method to obtain high-yield F(ab)2 suitable for clinical use from mouse IgGl. Mol Immunol 1991; 28:69-77; PMID:2011130; http://dx.doi.org/10.1016/0161-5890(91)90088-2
6. von Pawel-Rammingen U, Johansson BP, Bjorck L. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J 2002; 21:1607-15; PMID:11927545; http://dx.doi.org/10.1093/emboj/21.7.1607
7. Yamaguchi Y, Kim H, Kato K, Masuda K, Shimada I, Arata Y. Proteolytic fragmentation with high specificity of mouse immunoglobulin G. Mapping of proteolytic cleavage sites in the hinge region. J Immunol Methods 1995; 181:259-67; PMID:7745255; http://dx.doi.org/10.1016/0022-1759(95)00010-8
8. Scheer JM, Sandoval W, Elliott JM, Shao L, Luis E, Lewin-Koh SC, Schaefer G, Vandlen R. Reorienting the Fab domains of trastuzumab results in potent HER2 activators. PloS One 2012; 7:e51817; PMID:23284778; http://dx.doi.org/10.1371/journal.pone.0051817
9. Spiess C, Merchant M, Huang A, Zheng Z, Yang NY, Peng J, Ellerman D, Shatz W, Reilly D, Yansura DG, et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol 2013; 31:753-8; PMID:23831709; http://dx.doi.org/10.1038/nbt.2621
10. Junttila TT, Li J, Johnston J, Hristopoulos M, Clark R, Ellerman D, Wang BE, Li Y, Mathieu M, Li G, et al. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. Cancer Res 2014; 74:5561-71; PMID:25228655; http://dx.doi.org/10.1158/0008-5472.CAN-13-3622-T
11. Sun LL, Ellerman D, Mathieu M, Hristopoulos M, Chen X, Li Y, Yan X, Clark R, Reyes A, Stefanich E, et al. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med 2015; 7:287ra70; PMID:25972002; http://dx.doi.org/10.1126/scitranslmed.aaa4802
12. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993; 37:255-63; PMID:8102322; http://dx.doi.org/10.1007/BF01518520
13. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990; 50:1550-8; PMID:1689212
14. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2:127-37; PMID:12204533; http://dx.doi.org/10.1016/S1535-6108(02)00097-1
15. Eigenbrot C, Ultsch M, Dubnovitsky A, Abrahmsen L, Hard T. Structural basis for high-affinity HER2 receptor binding by an engineered protein. Proc Natl Acad Sci U S A 2010; 107:15039-44; PMID:20696930; http://dx.doi.org/10.1073/pnas.1005025107
16. Shalaby MR, Shepard HM, Presta L, Rodrigues ML, Beverley PC, Feldmann M, Carter P. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J Exp Med 1992; 175:217-25; PMID:1346155; http://dx.doi.org/10.1084/jem.175.1.217
17. Brennan M, Davison PF, Paulus H. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 1985; 229:81-3; PMID:3925553; http://dx.doi.org/10.1126/science.3925553
18. Glennie MJ, McBride HM, Worth AT, Stevenson GT. Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments. J Immunol 1987; 139:2367-75; PMID:2958547
19. Luo H, Hernandez R, Hong H, Graves SA, Yang Y, England CG, Theuer CP, Nickles RJ, Cai W. Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry. Proc Natl Acad Sci U S A 2015; 112:12806-11; PMID:26417085; http://dx.doi.org/10.1073/pnas.1509667112
20. Moore PA, Zhang W, Rainey GJ, Burke S, Li H, Huang L, Gorlatov S, Veri MC, Aggarwal S, Yang Y, et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 2011; 117:4542-51; PMID:21300981; http://dx.doi.org/10.1182/blood-2010-09-306449
21. James JR, Vale RD. Biophysical mechanism of T-cell receptor triggering in a reconstituted system. Nature 2012; 487:64-9; PMID:22763440; http://dx.doi.org/10.1038/nature11214
22. Bluemel C, Hausmann S, Fluhr P, Sriskandarajah M, Stallcup WB, Baeuerle PA, Kufer P. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother 2010; 59:1197-209; PMID:20309546; http://dx.doi.org/10.1007/s00262-010-0844-y
23. Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice. Cancer Res 1986; 46:3969-78; PMID:3731067
24. Quadri SM, Lai J, Mohammadpour H, Vriesendorp HM, Williams JR. Assessment of radiolabeled stabilized F(ab')2 fragments of monoclonal antiferritin in nude mouse model. J Nucl Med 1993; 34:2152-9; PMID:8254403
25. Honeychurch J, Tutt AL, Valerius T, Heijnen IA, Van De Winkel JG, Glennie MJ. Therapeutic efficacy of FcgammaRI/CD64-directed bispecific antibodies in B-cell lymphoma. Blood 2000; 96:3544-52; PMID:11071653
26. Parham P. On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice. J Immunol 1983; 131:2895-902; PMID:6358356
27. Serke S, van Lessen A, Huhn D. Quantitative fluorescence flow cytometry:a comparison of the three techniques for direct and indirect immunofluorescence. Cytometry 1998; 33:179-87; PMID:9773878; http://dx.doi.org/10.1002/(SICI)1097-0320(19981001)33:2%3c179::AID-CYTO12%3e3.0.CO;2-R